ELTX 8-K 2026-11-05

Elicio Therapeutics, Inc. (ELTX) 8-K dated 2026-11-05 — accession 0001601485-26-000065.

Elicio Therapeutics, Inc. (ELTX) is a biotechnology company listed on US.

Elicio Therapeutics, Inc. filed a 8-K on 2026-11-05. Accession 0001601485-26-000065.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported ELTX revenue for 2022-12-31 was $2.3M. Net income was -$38.8M. ELTX currently screens at market cap $132.3M.

Not investment advice. The ELTX SEC hub lists recent forms. The stock page is the research view.